Gyre Therapeutics (GYRE) Cash from Operations (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Cash from Operations of 3200000.0 for Q1 2026, up 2580.62% year-over-year from 119375.36 in Q1 2025, and up 157.25% quarter-over-quarter from 5590000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Cash from Operations (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Cash from Operations for 17 consecutive years, with 3200000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 2580.62% year-over-year to 3200000.0; the TTM figure through Mar 2026 stood at 4339000.0 (up 165.21% YoY), while the FY2025 annual figure was 1010000.0, up 127.74% from the prior year.
- Cash from Operations rose to 3200000.0 in Q1 2026 per GYRE's latest filing, from 5590000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 42298000.0 in Q4 2022 and bottomed at 12294000.0 in Q2 2022.
- Historically, Cash from Operations has averaged 2184588.24 across 5 years, with a median of 2129000.0 in 2025.
- Annual changes were most pronounced in 2024 — Cash from Operations tumbled 221.18% — and 2026, when it surged 2580.62%.
- Gyre Therapeutics' Cash from Operations stood at 42298000.0 in 2022, then slumped by 92.06% to 3360000.0 in 2023, then tumbled by 182.08% to 2758000.0 in 2024, then tumbled by 102.68% to 5590000.0 in 2025, then soared by 157.25% to 3200000.0 in 2026.
- Business Quant data shows GYRE's Cash from Operations at 3200000.0 in Q1 2026, 5590000.0 in Q4 2025, and 4600000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -16.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.75 Mn |
| Jun 30, 2026 | -16.75 Mn |
| Mar 31, 2026 | 3.20 Mn |
| Mar 31, 2026 | 3.20 Mn |
| Dec 31, 2025 | -5.59 Mn |
| Dec 31, 2025 | -5.59 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 2.13 Mn |
| Jun 30, 2025 | 2.13 Mn |
| Mar 31, 2025 | -129,000.00 |
| Mar 31, 2025 | -129,000.00 |
| Dec 31, 2024 | -2.76 Mn |
| Dec 31, 2024 | -2.76 Mn |
| Sep 30, 2024 | 1.73 Mn |
| Sep 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | -5.49 Mn |
| Jun 30, 2024 | -5.49 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Mar 31, 2024 | 2.88 Mn |